SYDNEY — Australia is preparing for the introduction of its first non-peptide oral GLP-1 receptor agonist, following the regulatory approval of orforglipron for use in clinical practice.
Endocrinologist Dr Ted Wu has highlighted that the new oral formulation significantly broadens access to GLP-1 therapy for patients managing type 2 diabetes and obesity. Unlike traditional injectable treatments, orforglipron offers an oral delivery method that aims to simplify administration for patients.
The medication is anticipated to arrive on Australian shelves within days. Healthcare professionals have noted that the arrival of orforglipron provides clinicians with practical new options for managing metabolic conditions, moving away from needle-based therapies while maintaining targeted GLP-1 treatment benefits.

